NYSE:PFE - Pfizer Stock Price, News, & Analysis

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer announced a quarterly dividend on Thursday, June 28th. Investors of record on Friday, August 3rd will be paid a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.23%. The ex-dividend date is Thursday, August 2nd. View Pfizer's Dividend History.

Pfizer announced that its board has initiated a stock buyback plan on Tuesday, December 19th 2017, which allows the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its stock is undervalued.

Pfizer Inc. (NYSE:PFE) posted its quarterly earnings data on Tuesday, July, 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.74 by $0.07. The biopharmaceutical company earned $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm's quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.67 EPS. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Pfizer.

Pfizer updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share guidance of $2.95-3.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.95. The company issued revenue guidance of $53-55 billion, compared to the consensus revenue estimate of $54.25 billion.

20 brokerages have issued 1 year target prices for Pfizer's stock. Their forecasts range from $37.00 to $45.00. On average, they anticipate Pfizer's share price to reach $41.1176 in the next twelve months. This suggests that the stock has a possible downside of 2.3%. View Analyst Price Targets for Pfizer.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

Pfizer saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 54,661,544 shares, an increase of 5.2% from the July 13th total of 57,638,413 shares. Based on an average trading volume of 20,733,428 shares, the short-interest ratio is currently 2.6 days. Currently, 0.9% of the company's shares are short sold. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

News stories about PFE stock have been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pfizer earned a news and rumor sentiment score of 0.09 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.48 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Pfizer.

Pfizer's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.65%), Bank of New York Mellon Corp (1.14%), Massachusetts Financial Services Co. MA (1.04%), Morgan Stanley (0.91%), Dimensional Fund Advisors LP (0.91%) and Fisher Asset Management LLC (0.66%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Russell Investments Group Ltd., Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado, Legal & General Group Plc, Advisors Asset Management Inc. and American Century Companies Inc.. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

PFE stock was acquired by a variety of institutional investors in the last quarter, including Charles Schwab Investment Advisory Inc., Dimensional Fund Advisors LP, Macquarie Group Ltd., Federated Investors Inc. PA, Jensen Investment Management Inc., Natixis, Fisher Asset Management LLC and Unigestion Holding SA. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $42.09.

Pfizer has a market capitalization of $243.65 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.